← Back to Screener
Tvardi Therapeutics, Inc. Common Stock (TVRD)
Price$3.15
Favorite Metrics
Price vs S&P 500 (26W)-58.76%
Price vs S&P 500 (4W)-18.69%
Market Capitalization$29.24M
All Metrics
Book Value / Share (Quarterly)$2.23
P/TBV (Annual)1.96x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-32.30%
Cash Flow / Share (Quarterly)$-2.50
Price vs S&P 500 (YTD)-29.05%
Gross Margin (TTM)100.00%
Net Profit Margin (TTM)-503.21%
EPS (TTM)$-8.36
10-Day Avg Trading Volume0.06M
EPS Excl Extra (TTM)$-8.36
Revenue Growth (5Y)-18.54%
EPS (Annual)$-46.60
ROI (Annual)-125.86%
Gross Margin (Annual)91.31%
Net Profit Margin (5Y Avg)-428.07%
Cash / Share (Quarterly)$3.28
Revenue Growth QoQ (YoY)20.33%
ROA (Last FY)-201.33%
Revenue Growth TTM (YoY)-55.30%
EBITD / Share (TTM)$-3.03
ROE (5Y Avg)-70.79%
Operating Margin (TTM)-435.07%
Cash Flow / Share (Annual)$-2.50
P/B Ratio1.40x
P/B Ratio (Quarterly)1.93x
Net Income / Employee (Annual)$-7
Net Interest Coverage (TTM)-0.05x
ROA (TTM)-33.69%
EPS Incl Extra (Annual)$-46.60
Current Ratio (Annual)2.86x
Quick Ratio (Quarterly)2.79x
3-Month Avg Trading Volume0.08M
52-Week Price Return-81.10%
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$2.20
P/S Ratio (Annual)4.10x
Asset Turnover (Annual)0.20x
52-Week High$43.65
Operating Margin (5Y Avg)-418.22%
EPS Excl Extra (Annual)$-46.60
CapEx CAGR (5Y)120.65%
26-Week Price Return-51.87%
Quick Ratio (Annual)2.79x
13-Week Price Return-28.60%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)2.86x
Enterprise Value$8.502
Revenue / Share Growth (5Y)58.71%
Asset Turnover (TTM)0.15x
Revenue / Employee (Annual)$1
Inventory Turnover (Annual)0.33x
Pretax Margin (Annual)-998.53%
Cash / Share (Annual)$3.28
3-Month Return Std Dev60.59%
Net Income / Employee (TTM)$-1
ROE (Last FY)-207.61%
EPS Basic Excl Extra (Annual)$-46.60
Receivables Turnover (TTM)5.14x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-8.36
ROI (TTM)-4.47%
P/S Ratio (TTM)3.86x
Pretax Margin (5Y Avg)-429.29%
Revenue / Share (Annual)$4.69
Tangible BV / Share (Annual)$2.20
Price vs S&P 500 (52W)-115.73%
Year-to-Date Return-25.12%
5-Day Price Return1.90%
EPS Normalized (Annual)$-46.60
ROA (5Y Avg)-75.02%
Net Profit Margin (Annual)-992.95%
Month-to-Date Return1.26%
EBITD / Share (Annual)$-48.59
Operating Margin (Annual)-919.43%
LT Debt / Equity (Annual)0.65x
ROI (5Y Avg)-54.44%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-8.36
P/TBV (Quarterly)1.96x
P/B Ratio (Annual)1.93x
Inventory Turnover (TTM)0.00x
Pretax Margin (TTM)-508.47%
Book Value / Share (Annual)$2.23
Price vs S&P 500 (13W)-30.98%
Beta0.32x
P/FCF (Annual)10.37x
Revenue / Share (TTM)$4.97
ROE (TTM)-4.47%
52-Week Low$2.75
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
3.86
3.86
3.93
3.93
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
TVRDTvardi Therapeutics, Inc. Common Stock | 3.86x | -55.30% | 100.00% | — | $3.15 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $899.91 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $224.87 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $205.74 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $112.62 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $196.15 |
NVSNovartis AG | 4.93x | 8.91% | 75.82% | 15.26% | $148.70 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $38.87 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $94.12 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.37 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $58.80 |
About
Tvardi Therapeutics is a clinical-stage biopharmaceutical company developing oral small molecule therapies that target STAT3 for fibrosis-driven diseases. Its lead candidate, TTI-101, is in Phase 2 development for idiopathic pulmonary fibrosis and hepatocellular carcinoma. The company also has a second product candidate, TTI-109, designed to enhance STAT3 targeting.